Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, 200233, China; Nanjing First Hospital, Nanjing, 210029, China; The Second Hospital Affiliated to Nanjing Medical University, Nanjing, 210011, China; The First Hospital Affiliated to Anhui Medical University, Hefei, 230031, China; The First People's Hospital of Yueyang, Yueyang, 414000, China; PLA Rocket Force Characteristic Medical Center, Beijing, 100085, China; Huai'an First People's Hospital, Huai'an, 223300, China; The Central Hospital of Minhang District of Shanghai, Shanghai, 201100, China; The Second Hospital of Heibei Medical University, Shijiazhuang, 050000, China; Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, 100730, China; The First Hospital of Jilin University, Changchun, 130021, China; Tongji Hospital of Tongji University, Shanghai, 200092, China; The Qingpu Branch of Zhongshan Hospital Affiliate to Fudan University, Shanghai, 201700, China; Siping Central People's Hospital, Siping, 136000, China; Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China; The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China; The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China; The First Affiliated Hospital of Guangxi Medical University (The Western Hospital), Nanning, 530021, China; Gulou Hospital Affiliated to Nanjing Medical University, Nanjing, 210008, China; The First Affiliated Hospital of Guangxi Medical University (The Eastern Hospital), Nanning, 530021, China; Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China; The General Hospital of the Chinese People's Armed Police Forces, Beijing, 100022, China; The Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China; Zhongshan People's Hospital, Zhongshan, 528403, China; The Third Hospital Affiliated to Guangzhou Medical College, Guangzhou, 510150, China; Fuwai Hospital, Beijing, 100037, China; Shanghai First People's Hospital, Shanghai, 200080, China; Shanghai 5th People's Hospital, Shanghai, 200040, China; The Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, China; The Affiliated Hospital of Inner Mongolia, Hohhot, 000306, China; Shenzhen Second People's Hospital, Shenzhen, 518035, China; Anhui Provincial Hospital, Hefei, 518035, China; Beijing University Shenzhen Hospital, Shenzhen, 518036, China; Shenzhen Chipscreen Biosciences, Ltd., Shenzhen, 518057, China; Peking University People's Hospital, Beijing, 100044, China
Recommended Citation:
Jia W.,Ma J.,Miao H.,et al. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)[J]. Science Bulletin,2021-01-01,66(15)